Compounds as antagonists or inverse agonists at opioid receptors
Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.
1. A compound which is N-{[3,5-difluoro-3′-(1H-1,2,4-triazol-3-yl)-4-biphenylyl]methyl}-2,3-dihydro-1H-inden-2-amine which is
or a salt thereof.
2. A pharmaceutical composition comprising a compound of claim 1 or a salt thereof and at least one excipient.
3. The compound of claim 1 which is a citrate, phosphate or mono- or di-hydrochloride salt.
4. The compound of claim 3 which is a citrate salt of N-{[3,5-difluoro-3′-(1H-1,2,4-triazol-3-yl)-4-biphenylyl]methyl}-2,3-dihydro-1H-inden-2-amine.
5. The compound of claim 3 which is a phosphate salt of N-{[3,5-difluoro-3′-(1H-1,2,4-triazol-3-yl)-4-biphenylyl]methyl}-2,3-dihydro-1H-inden-2-amine.
6. The compound of claim 3 which is a mono-hydrochloride salt of N-{[3,5-difluoro-3′-(1H-1,2,4-triazol-3-yl)-4-biphenylyl]methyl}-2,3-dihydro-1H-inden-2-amine.
7. The compound of claim 3 which is a di-hydrochloride salt of N-{[3,5-difluoro-3′-(1H-1,2,4-triazol-3-yl)-4-biphenylyl]methyl}-2,3-dihydro-1H-inden-2-amine.
8. A method of treatment comprising administering a pharmaceutical composition comprising (i) a compound of claim 1 or a salt thereof and (ii) at least one carrier to a human suffering from the condition of obesity.
9. A method of treatment comprising administering to a human a compound of claim 1 or a salt thereof, wherein said treatment is obesity.